← Back to Search

Behavioral Intervention

Gamification for Dementia

N/A
Waitlist Available
Led By Ryan Greysen, MD, MHS, MA
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 week intervention period (weeks 1 - 12)
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if a fun game can help older adults walk more to prevent Alzheimer's. Participants set daily step goals and get support from a partner. The game aims to make walking a long-term habit.

Eligible Conditions
  • Dementia
  • Memory Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 week intervention period (weeks 1 - 12)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 week intervention period (weeks 1 - 12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Mean Daily Steps From the Baseline Period to the End of the 12 Week Intervention Period.
Secondary study objectives
Change in Mean Daily Step Counts During the 6 Week Follow-up Period After the End of the Intervention Period Tracked by Fitbit Inspire Device.
Other study objectives
Change in Moderate-vigorous Physical Activity (MVPA) Minutes During the Baseline and Follow-up Period (Weeks 13-18).
Change in Moderate-vigorous Physical Activity Minutes (MVPA) During the Start of the Intervention Period Compared to Baseline Period.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GamificationExperimental Treatment1 Intervention
Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 12-week intervention period. At the end of the 12 week intervention period, participants will enter a 6 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design.
Group II: ControlActive Control1 Intervention
Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gamification
2019
Completed Phase 3
~3090

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,076 Previous Clinical Trials
42,719,585 Total Patients Enrolled
20 Trials studying Dementia
37,847 Patients Enrolled for Dementia
National Institute on Aging (NIA)NIH
1,788 Previous Clinical Trials
28,184,532 Total Patients Enrolled
292 Trials studying Dementia
23,634,498 Patients Enrolled for Dementia
Ryan Greysen, MD, MHS, MAPrincipal InvestigatorUniversity of Pennsylvania
4 Previous Clinical Trials
717 Total Patients Enrolled
~60 spots leftby Nov 2025